Clinical trial
Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100…
NCT00445302 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00445302 |
|---|---|
| Title | Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment |
| Official title | A Phase I Study Of The Safety, Pharmacokinetics, And Hematological Activity Of AMD3100 (240 µg/kg) In Subjects With Renal Impairment |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Renal Impairment |
| Intervention type | Drug |
| Interventions | plerixafor |
| Enrollment | 23 |
| Start date | Jan 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Mar 8, 2007 |
| Last update posted | Mar 13, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: